Authors
Latest:
Experts Discuss the Risk of Skin Toxicities Associated With EGFR TKIsJeanne G. Vaughn, NP, Kristina Lo, PharmD, BCOP, Jonathan Riess, MD, MS, and Ticiana Leal, MD, discuss the impact of skin toxicities when utilizing EGFR TKIs.
Latest:
Dr Richardson on Escalating Rates of Uterine Cancer Among Asian AmericansMichael Richardson, MD, discusses escalating uterine cancer rates among Asian Americans.
Latest:
Dr Liu on the Frequency of Activating ERBB2 and ERBB3 Alterations in NSCLCDazhi Liu, PharmD, MS, BCOP, discusses findings from a real-world analysis of the frequency of ERBB2 and ERBB3 alterations in patients with non–small cell lung cancer and the efficacy of liquid vs tissue biopsies for detecting these alterations.
Latest:
Pembrolizumab Plus Chemo Could Represent a New SOC in Advanced/Recurrent Endometrial CancerRamez N. Eskander, MD, discusses updated data for pembrolizumab plus chemotherapy in patients with advanced/recurrent endometrial cancer.
Latest:
Dr Plichta on Areas of Interest for Genetic Testing Research in Breast CancerJennifer K. Plichta, MD, MS, discusses key areas of interest regarding the role and optimization of genetic testing in breast cancer.
Latest:
Dr Myall on Immunotherapy Doublets and Chemoimmunotherapy in NSCLCNathaniel Myall, MD, clinical assistant professor, medicine - oncology, Stanford Medicine, discusses efficacy findings from 3 clinical trials investigating combination immunotherapy and chemoimmunotherapy treatment approaches in patients with non–small cell lung cancer.
Latest:
Advice for Community Oncologists Treating Patients With R/R MMDrs Lipe and Forsberg share advice for community oncologists and highlight unmet needs in the management of multiple myeloma.
Latest:
Evolving Treatment Landscape of MyelofibrosisClosing out their discussion on myelofibrosis management, experts from the John Theurer Cancer Center consider novel therapies under investigation and the future treatment paradigm.
Latest:
Dr. Rosenberg on Adapting Treatment Decisions Based on MRD in Multiple MyelomaAaron Seth Rosenberg, MD, MS, discusses the emerging role of minimal residual disease to guide treatment decisions in multiple myeloma.
Latest:
Dr. Galligan on Unmet Needs in High-Risk Multiple MyelomaDerek C. Galligan, MD, discusses unmet needs in high-risk multiple myeloma.
Latest:
Dr. Greenlee on Mitigating the Risk of Cardiovascular Disease in Breast CancerHeather Greenlee, ND, PhD, MPH, provides strategies to mitigate the increased risk of cardiovascular disease in women with breast cancer.
Latest:
Dr Montesinos on Quizartinib Plus Chemotherapy in Newly Diagnosed FLT3-ITD Wild-Type AMLPau Montesinos, MD, PhD, discusses preliminary efficacy seen with the addition of quizartinib to standard 7+3 chemotherapy in patients with newly diagnosed FLT3-ITD wild-type acute myeloid leukemia.
Latest:
Mentoring Oncologists in the Era of Social DistancingMentoring is critically important to the development of young academic hematology/oncology trainees.
Latest:
FRESCO-2: A Global Phase 3 Multiregional Clinical Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients With Refractory Metastatic Colorectal CancerArvind Dasari, MD, MS, presents data from the FRESCO-2 clinical trial evaluating fruquintinib in patients with refractory metastatic colorectal cancer, and provides insights on the clinical implications of the results.
Latest:
Dr. von Mehren on Outcomes With Ribociclib/Everolimus in Dedifferentiated LiposarcomaMargaret von Mehren, MD, discusses outcomes with ribociclib and everolimus in dedifferentiated liposarcoma, as seen in the phase 2 SAR-096 trial.
Latest:
Dr. Abutalib on Recent Updates in CLLSyed A. Abutalib, MD, associate medical director, Hematologic Malignancies and Stem Cell Transplant Program, Cancer Treatment Centers of America, discusses recent updates in chronic lymphocytic leukemia.
Latest:
Dr. Moutafi on the Results of a Study Evaluating Biomarkers of Resistance in NSCLCMyrto Moutafi, MD, MSc, discusses the results of a study evaluating biomarkers of resistance in non–small cell lung cancer.
Latest:
Dr. Lazar on the Current State of Diagnosis and Treatment in Desmoid TumorsAlexander J. Lazar, MD, PhD, discusses the current state of diagnosis and treatment in desmoid tumors.
Latest:
Dr. Romancik on Maximizing CAR T-cell Therapy in NHLJason Romancik, MD, discusses efforts to maximize the efficacy of CAR T-cell therapy in non-Hodgkin lymphoma.
Latest:
Dr. Blanter on Racial Disparities in Development of Distant Metastases in Breast CancerJulia Blanter, MD, discusses the risk of developing distant metastases after initial breast cancer diagnosis among Black vs White women.
Latest:
Dr Gangat on the Evolution of JAK Inhibitors in MyelofibrosisNaseema Gangat, MBBS, on evolution of JAK inhibitors for the treatment of patients with myelofibrosis.
Latest:
Dr. Tiwari on Ongoing Research in HER2+/HER2-Low Breast CancerShruti Tiwari, MD, discusses efforts to address unmet needs through ongoing research in HER2-positive and HER2-low breast cancer.
Latest:
Biomarkers Drive ICIs in Colon CancerDecember 14, 2020 - Immunotherapy agents have shown efficacy in malignant melanoma, kidney cancer, and non–small cell lung cancer, and investigators are examining the efficacy of checkpoint inhibitors in less immunogenic tumors such as colon cancer, particularly in tumors with high microsatellite instability and deficient mismatch repair genes.
Latest:
Siteman Cancer Center Names New Deputy Director Among Other Leadership AppointmentsSiteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis announces several leadership changes, including a new Deputy Director, Associate Directors of Translational Research and Shared Resources, and a Deputy Associate Director of Shared Resources.
Latest:
Dr DePalo on First-Line Therapies in Unresectable Melanoma In-Transit MetastasesDanielle K. DePalo, MD, discusses findings from a study comparing first-line isolated limb infusion/perfusion vs immune checkpoint inhibitors and intratumoral therapy in patients with surgically unresectable melanoma in-transit metastases.
Latest:
Dr. Maron on the Role of PD-1 Inhibition in Esophagogastric CancerSteven Maron, MD, MSc, discusses the role of PD-1 inhibition in esophagogastric cancer.
